Latest Insider Transactions at Biomarin Pharmaceutical Inc (BMRN)
This section provides a real-time view of insider transactions for Biomarin Pharmaceutical Inc (BMRN). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of BIOMARIN PHARMACEUTICAL INC to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of BIOMARIN PHARMACEUTICAL INC's insiders and make more informed investment decisions.
Insider Transaction List
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Jan 10
2024
|
Jean Jacques Bienaime Director |
BUY
Exercise of conversion of derivative security
|
Direct |
10,000
+2.25%
|
$630,000
$63.1 P/Share
|
|
Jan 09
2024
|
Jean Jacques Bienaime Director |
SELL
Open market or private sale
|
Direct |
10,000
-2.3%
|
$980,000
$98.19 P/Share
|
|
Jan 09
2024
|
Jean Jacques Bienaime Director |
BUY
Exercise of conversion of derivative security
|
Direct |
10,000
+2.25%
|
$630,000
$63.1 P/Share
|
|
Jan 08
2024
|
Richard A Meier Director |
SELL
Bona fide gift
|
Direct |
3,000
-2.6%
|
-
|
|
Jan 08
2024
|
Jean Jacques Bienaime Director |
BUY
Small Acquisition
|
Direct |
50
+0.01%
|
$4,950
$99.05 P/Share
|
|
Dec 27
2023
|
Barbara W. Bodem Director |
BUY
Grant, award, or other acquisition
|
Direct |
2,180
+50.0%
|
-
|
|
Dec 27
2023
|
Mark J Enyedy Director |
BUY
Grant, award, or other acquisition
|
Direct |
2,180
+50.0%
|
-
|
|
Dec 27
2023
|
Athena Countouriotis Director |
BUY
Grant, award, or other acquisition
|
Direct |
2,180
+50.0%
|
-
|
|
Dec 21
2023
|
Jean Jacques Bienaime Director |
SELL
Open market or private sale
|
Direct |
10,000
-2.3%
|
$930,000
$93.99 P/Share
|
|
Dec 21
2023
|
Jean Jacques Bienaime Director |
BUY
Exercise of conversion of derivative security
|
Direct |
10,000
+2.25%
|
$630,000
$63.1 P/Share
|
|
Dec 13
2023
|
George Eric Davis EVP, Chief Legal Officer |
SELL
Open market or private sale
|
Direct |
13,764
-19.81%
|
$1,307,580
$95.3 P/Share
|
|
Dec 01
2023
|
Jean Jacques Bienaime Director |
BUY
Grant, award, or other acquisition
|
Direct |
2,370
+0.55%
|
-
|
|
Dec 01
2023
|
Alexander Hardy Chief Executive Officer |
BUY
Grant, award, or other acquisition
|
Direct |
115,371
+39.55%
|
-
|
|
Dec 01
2023
|
Henry J Fuchs President, Worldwide R&D |
BUY
Grant, award, or other acquisition
|
Direct |
17,750
+8.37%
|
-
|
|
Dec 01
2023
|
Charles Greg Guyer EVP, Chief Technical Officer |
BUY
Grant, award, or other acquisition
|
Direct |
11,840
+18.54%
|
-
|
|
Oct 31
2023
|
Charles Greg Guyer EVP, Chief Technical Officer |
BUY
Grant, award, or other acquisition
|
Direct |
133
+0.33%
|
$9,177
$69.23 P/Share
|
|
Oct 04
2023
|
Jean Jacques Bienaime Director |
BUY
Small Acquisition
|
Direct |
10
+0.0%
|
$850
$85.57 P/Share
|
|
Aug 16
2023
|
Jeffrey Robert Ajer EVP, Chief Commercial Officer |
SELL
Open market or private sale
|
Direct |
5,000
-7.6%
|
$450,000
$90.0 P/Share
|
|
Aug 10
2023
|
Henry J Fuchs President, Worldwide R&D |
SELL
Open market or private sale
|
Direct |
12,000
-6.38%
|
$1,080,000
$90.43 P/Share
|
|
Aug 09
2023
|
Charles Greg Guyer EVP, Chief Technical Officer |
SELL
Open market or private sale
|
Direct |
5,360
-11.81%
|
$498,480
$93.3 P/Share
|
|
Aug 08
2023
|
Jean Jacques Bienaime Director |
SELL
Open market or private sale
|
Direct |
6,000
-1.4%
|
$528,000
$88.29 P/Share
|
|
Aug 08
2023
|
George Eric Davis EVP, Chief Legal Officer |
SELL
Open market or private sale
|
Direct |
11,000
-13.67%
|
$979,000
$89.42 P/Share
|
|
Aug 07
2023
|
Jean Jacques Bienaime Director |
SELL
Open market or private sale
|
Direct |
4,000
-0.92%
|
$352,000
$88.1 P/Share
|
|
Jun 29
2023
|
Brian Mueller EVP, Chief Financial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
9,780
-6.18%
|
$860,640
$88.93 P/Share
|
|
May 23
2023
|
Willard H Dere Director |
BUY
Grant, award, or other acquisition
|
Direct |
4,190
+13.19%
|
-
|
|
May 23
2023
|
Elaine J Heron Director |
BUY
Grant, award, or other acquisition
|
Direct |
4,190
+4.35%
|
-
|
|
May 23
2023
|
Maykin Ho Director |
BUY
Grant, award, or other acquisition
|
Direct |
4,190
+20.12%
|
-
|
|
May 23
2023
|
Robert J. Hombach Director |
BUY
Grant, award, or other acquisition
|
Direct |
4,190
+12.08%
|
-
|
|
May 23
2023
|
V Bryan Lawlis Director |
BUY
Grant, award, or other acquisition
|
Direct |
4,190
+11.22%
|
-
|
|
May 23
2023
|
Richard A Meier Director |
BUY
Grant, award, or other acquisition
|
Direct |
4,190
+3.5%
|
-
|
|
May 23
2023
|
David E I Pyott Director |
BUY
Grant, award, or other acquisition
|
Direct |
4,190
+8.51%
|
-
|
|
May 23
2023
|
Dennis Slamon Director |
BUY
Grant, award, or other acquisition
|
Direct |
4,190
+11.97%
|
-
|
|
May 23
2023
|
Mark J Alles Director |
BUY
Grant, award, or other acquisition
|
Direct |
4,190
+21.73%
|
-
|
|
May 23
2023
|
Elizabeth M Anderson Director |
BUY
Grant, award, or other acquisition
|
Direct |
4,190
+15.36%
|
-
|
|
May 16
2023
|
Erin Burkhart GVP, Chief Accounting Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
796
-5.35%
|
$73,232
$92.02 P/Share
|
|
May 16
2023
|
George Eric Davis EVP, Chief Legal Officer |
SELL
Bona fide gift
|
Direct |
210
-0.26%
|
-
|
|
May 12
2023
|
Elaine J Heron Director |
SELL
Payment of exercise price or tax liability
|
Direct |
6,137
-6.52%
|
$570,741
$93.93 P/Share
|
|
May 12
2023
|
Elaine J Heron Director |
BUY
Exercise of conversion of derivative security
|
Direct |
8,500
+8.29%
|
$569,500
$67.81 P/Share
|
|
May 12
2023
|
Richard A Meier Director |
SELL
Payment of exercise price or tax liability
|
Direct |
6,137
-5.22%
|
$570,741
$93.93 P/Share
|
|
May 12
2023
|
Richard A Meier Director |
BUY
Exercise of conversion of derivative security
|
Direct |
8,500
+6.75%
|
$569,500
$67.81 P/Share
|
|
May 12
2023
|
Jean Jacques Bienaime Director |
SELL
Payment of exercise price or tax liability
|
Direct |
39,981
-4.28%
|
$3,718,233
$93.93 P/Share
|
|
May 12
2023
|
Jean Jacques Bienaime Director |
BUY
Exercise of conversion of derivative security
|
Direct |
46,500
+4.65%
|
$3,115,500
$67.81 P/Share
|
|
May 11
2023
|
Jean Jacques Bienaime Director |
SELL
Open market or private sale
|
Direct |
30,000
-3.32%
|
$2,820,000
$94.89 P/Share
|
|
May 11
2023
|
Jean Jacques Bienaime Director |
BUY
Exercise of conversion of derivative security
|
Direct |
30,000
+6.17%
|
$2,010,000
$67.81 P/Share
|
|
May 10
2023
|
Jean Jacques Bienaime Director |
SELL
Open market or private sale
|
Direct |
30,000
-3.33%
|
$2,820,000
$94.99 P/Share
|
|
May 10
2023
|
Jean Jacques Bienaime Director |
BUY
Exercise of conversion of derivative security
|
Direct |
30,000
+6.17%
|
$2,010,000
$67.81 P/Share
|
|
May 09
2023
|
Jean Jacques Bienaime Director |
SELL
Open market or private sale
|
Direct |
30,000
-2.23%
|
$2,850,000
$95.2 P/Share
|
|
May 09
2023
|
Jean Jacques Bienaime Director |
BUY
Exercise of conversion of derivative security
|
Direct |
30,000
+6.17%
|
$2,010,000
$67.81 P/Share
|
|
May 04
2023
|
Charles Greg Guyer EVP, Chief Technical Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
4,302
-8.66%
|
$408,690
$95.45 P/Share
|
|
Apr 28
2023
|
Henry J Fuchs President, Worldwide R&D |
BUY
Grant, award, or other acquisition
|
Direct |
317
+0.18%
|
$20,922
$66.88 P/Share
|